Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2010

View Archived Issues

Lilly presents inhibitors of hedgehog signaling for cancer therapy

Muscular Dystrophy Association and ALS TDI strengthen partnership

Seaside Therapeutics and Vanderbilt University enter into research agreement

Quark Pharmaceuticals to advance siRNA QPI-1002 into clinical studies

Ensemble Discovery initiates collaboration with Pfizer

Ardea Biosciences reports positive results for RDEA-594 in patients with gout

MabCure launches trial of monoclonal antibodies to diagnose ovarian cancer

Strategic Diagnostics and Fred Hutchinson Cancer Research Center collaborate on cancer biomarkers

Hawaii Biotech completes dosing in phase I trial of dengue virus vaccine

Hepatitis C therapeutic filibuvir safe and well tolerated in phase I-II studies

Results reported from first-in-human trial of hepatitis C therapeutic ABT-072

Leptin beneficial in patients with various forms of lipodystrophy

Protease inhibitor BI-201335 potent in clinical studies in hepatitis C

BIT-225 shows modest antiviral efficacy in phase Ib trial in hepatitis C

Access Pharmaceuticals completes ProLindac monotherapy trial

3SBio applies for registrational trial of Feraheme in China

Agennix discloses Plk-1 inhibitors for cancer therapy

Joyant Pharmaceuticals identifies novel antineoplastic agents

National Health Research Institutes identify aurora A kinase inhibitors for cancer therapy

Takeda claims novel protein kinase inhibitors for cancer therapy

NexBio initiates phase II trial of influenza therapy DAS-181

Tolerx completes enrollment in phase III DEFEND-1 study in type 1 diabetes

Siena Biotech commences first clinical trial of sirtuin inhibitor EX-527

Tekmira Pharmaceuticals completes phase I clinical trial of ApoB SNALP

OraSure Technologies files PMA amendment with FDA for OraQuick Rapid HCV Antibody Test

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...